Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Lumito AB (publ) ("Lumito" or the "Company") today announces that the members of the Nomination Committee ahead of Lumito's 2026 Annual General Meeting have been appointed.

In accordance with the instructions for the Nomination Committee adopted at the 2022 Annual General Meeting, Lumito's Nomination Committee shall consist of three members. The Nomination Committee is formed by the Chairman of the Board, who, based on shareholder statistics as of the last banking day in September from Euroclear Sweden AB, contacts the three largest shareholders by voting rights. Each of these shareholders has the right to appoint one representative to the nomination committee.

The Nomination Committee is composed as follows:

The primary responsibility of the Nomination Committee is to prepare proposals for the election of board members and for the remuneration of the board. Furthermore, the Nomination Committee shall submit proposals regarding the auditor, the Chairman of the Meeting, and, where deemed necessary, amendments to the instructions for the Nomination Committee.

Shareholders wishing to submit proposals to the Nomination Committee may do so by email to: [email protected] or in writing to the following address:Lumito ABAtt: Nomination CommitteeScheelevägen 19223 63 LundSweden

Proposals must be received by the Nomination Committee no later than 27 February 2026.

The Nomination Committee's proposals will be presented well in advance of the Annual General Meeting and published on the Company's website in conjunction with this.

The Annual General Meeting will be held on Thursday, 7 May 2026, at Lumito's offices, Scheelevägen 19, 223 63 Lund.

For further information, please contact:Kerstin Jakobsson, Chairman of the Board, Lumito ABE-post: [email protected] Mobil: +46 70-550 45 40

About LumitoLumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

AttachmentsNomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting